Investors Cheer Lantheus' Wall Street-Beating FY22 Outlook

Lantheus Holdings Inc LNTH reported Q4 sales of $129.6 million, +37.6% Y/Y, beating the consensus of $111.76 million.

• The company's Q4 adjusted EPS reached $0.25, higher than $0.07 reported a year ago, better than the consensus of $0.17.
• Free Cash Flow was $9.3 million for Q4 of 2021 compared to $(3.2) million for Q4 of 2020.
• The gross margin improved to 44.7% from 41.1% a year ago.
• Yesterday, the FDA approved a supplemental application for Lantheus' isolator-based drug manufacturing facility for Definity (Perflutren Lipid Microsphere), a diagnostic ultrasound enhancing agent.
• Guidance: Lantheus forecasts FY22 sales of $685 million - $710 million, well above the consensus of $481.73 million.
• The company expects FY22 adjusted EPS of $1.95 - $2.05, versus the consensus of $0.89.
• For Q1 FY22, the company expects sales of $160 million - $170 million, surpassing the consensus of $113.57 million.
• It expects adjusted EPS of $0.45 - $0.50, well above the Street estimate of $0.17.
• Separately, Palette Life Sciences agreed to promote Lantheus' Pylarify (piflufolastat F 18) in the U.S, a PSMA-targeted PET imaging agent, to determine the presence of recurrent/metastatic prostate cancer. 
• Lantheus will compensate Palette on a fee-for-service basis and maintain responsibility for all other aspects of Pylarify commercialization.
• Price Action: LNTH shares are up 29.5% at $37.37 during the premarket session on the last check Thursday.